PAM
SYRE icon

Panagora Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Panagora Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-33
Closed -$6K – 2600
2019
Q4 		$6K Hold
33
– – ﹤0.01% 2216
2019
Q3 		$6K Sell
33
-51
-61% -$9.93K ﹤0.01% 2261
2019
Q2 		$14K Buy
+84
New +$14.5K ﹤0.01% 2352
2018
Q2 		– Sell
-639
Closed -$158K – 2420
2018
Q1 		$158K Hold
639
– – ﹤0.01% 1738
2017
Q4 		$86K Buy
639
+151
+31% +$18.5K ﹤0.01% 1923
2017
Q3 		$58K Sell
488
-105
-18% -$9.84K ﹤0.01% 2026
2017
Q2 		$57K Buy
+593
New +$82K ﹤0.01% 2034

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Panagora Asset Management's SYRE Position: Q1 2020 in Review

Panagora Asset Management sold out of Spyre Therapeutics (SYRE) in Q1 2020, closing a stake of 33 shares — an estimated $6K sold.

Panagora Asset Management first reported a position in SYRE in Q2 2017 and held it in 7 quarters. The position peaked at $158K in Q1 2018. 70 funds tracked by Wall St. Rank hold SYRE as of Q1 2020.

  • Panagora Asset Management reported no remaining Spyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Panagora Asset Management sold 33 Spyre Therapeutics shares in Q1 2020, an estimated $6K.
  • Panagora Asset Management first reported a position in Spyre Therapeutics in Q2 2017 and held it in 7 quarters.
  • Panagora Asset Management's Spyre Therapeutics position peaked at $158K in Q1 2018.
  • 70 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2020.

Based on Panagora Asset Management's 13F filing for Q1 2020, filed 14 May 2020.